Biotech Startups

Aukera Therapeutics is a preclinical-stage biotech company, spun out of the University of Basel's Biozentrum, developing the first RAPTOR inhibitors to treat mTORC1-related diseases. It pairs mTOR pathway expertise with an AI-driven drug discovery engine aimed at complex, hard-to-drug targets.

1 investor

Auni Therapeutics develops immunotherapy treatments for food allergies, leveraging intralymphatic immunotherapy (ILIT) protocols and proprietary clinical innovations. The company serves patients with allergic disease and aims to bring next-generation allergen immunotherapies to market.

1 investor

Aurealis Therapeutics is a clinical-stage synthetic biology company developing multi-targeting cell and gene therapies for chronic wounds, cancers, and inflammatory diseases. Its platform targets conditions such as diabetic foot ulcers, venous leg ulcers, and ovarian, peritoneal, bladder, and recurrent melanoma cancers.

1 investor

Aureka Biotechnologies is a tech-bio startup that combines high-throughput digital biology data with generative AI to discover protein and antibody therapeutics. It is developing an internal pipeline of antibody treatments targeting cardiometabolic and inflammatory diseases.

1 investor

Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease. Its lead program, AURN001, is a combination therapy made from human donor endothelial cells intended to restore corneal clarity as an alternative to donor corneal transplantation.

1 investor

Auristone builds an epigenomic database focused on Asian cohorts and diseases to enable drug and biomarker discoveries. The company develops proprietary predictive models based on epigenomics data across cancer types to provide clinical insights that complement genomic information.

1 investor

Aurora develops a platform for personalized gene editing to treat rare genetic diseases at scale. The company targets patients with rare disease variants by systematizing and scaling gene editing treatments to address genetic mutations that lack existing therapeutic options.

1 investor

AusBiotech is the national industry association representing Australia's life sciences ecosystem, advocating for policy, facilitating connections, and supporting growth for biotechnology, medical technologies, and digital health companies.

1 investor

1 investor

Austrianova is a biotech company that manufactures cell-based products using encapsulation technology and GMP-grade processes. The company serves pharmaceutical and biotech firms developing cell therapies, with quality systems and data infrastructure based in Germany and Switzerland.

1 investor

AustroCel Hallein is a biorefinery company that processes wood into biochemical and bioenergy products with a focus on sustainability. The company operates as one of Europe's leading integrated biorefineries, leveraging wood resources across the full value chain.

1 investor

AutoGenomics develops genetic testing platforms for clinical reference labs, specialty clinics, and hospital laboratories. The company's microarray technology enables multiplexed genetic marker detection and analysis for personalized medicine diagnostics.

1 investor

AutoIVF builds chip-based microfluidic systems that automate embryology steps in IVF laboratories, including its OvaReady product for oocyte preparation using a software-controlled instrument and single-use microfluidic kit. It targets IVF clinics and fertility labs, aiming to reduce operator variability and standardize laboratory workflows.

1 investor

Automera develops an autophagy-powered small molecule degrader platform designed to accelerate drug development and reduce costs in therapeutic creation. The company targets pharmaceutical and biotech organizations seeking novel technologies for small molecule drug discovery.

1 investor

Autonomy Bio is a biotech company developing drugs targeting human aging to extend healthy lifespan.

1 investor

Aeris Biosciences (formerly Auxilium Health) develops biomaterials for regenerative medicine. The company is composed of scientists, engineers, and clinicians working in the human health field.

1 investor

Auxilius Pharma develops value-added cardiovascular medications by reformulating existing drugs into optimized dosage forms to improve patient outcomes. The company serves patients, healthcare providers, and payors by addressing unmet needs in cardiovascular health through enhanced drug delivery.

1 investor

Avana Health is a women's health company developing uterine health treatments for abnormal uterine bleeding (AUB) and postpartum hemorrhage (PPH), and is preparing for its first clinical trials. Its treatments target unmet needs in maternal and gynecological care and are intended to be affordable and accessible to providers globally.

1 investor

Avant Genomics is developing an automated platform for liquid biopsy sample preparation, using an enclosed fluidic cartridge and benchtop instruments that integrate DNA enrichment and purification for blood-based cancer detection. The system targets research labs, clinical testing environments, and reference laboratories aiming to reduce manual labor and cost in precision oncology workflows.

1 investor

VWR (part of Avantor) is a distributor of laboratory and production products and services, offering life science reagents, chemicals, lab equipment, consumables, safety/PPE, and furniture. It also provides procurement, supply chain, equipment servicing, and digital commerce/inventory software for research, biopharma, healthcare, and industrial customers.

1 investor

Avanzanite is a biopharmaceutical commercialization and distribution company that partners with emerging research-based drug originators to license and distribute approved orphan (rare disease) medicines across European markets. It operates as an authorized wholesaler within the European Economic Area, aiming to expand patient access to rare disease treatments across 30+ European countries.

1 investor

Aventera Antibodies is a preclinical biotech developing a first-in-class precision immunotherapy — an engineered monoclonal antibody — against invasive Group A Streptococcal (iGAS) infections, with first-in-human trials planned for 2028. The therapy is intended to be paired with rapid Strep-A diagnostics to enable early clinical intervention.

1 investor

Aventi is a clinical-stage biopharmaceutical company developing therapeutics for sarcopenia, with plans to treat geriatric sarcopenia and expand to other age-related diseases. It operates in the biotechnology and pharmaceutical industry.

1 investor

AVEO, operating as a subsidiary of LG Chem, develops and commercializes oncology medicines aimed at cancer patients seeking effective treatments that maintain quality of life. The company operates a portfolio of on-market and in-development therapeutic products globally.

1 investor